The presentation of updated data from a Phase 1 study is a significant event for a biotech company like Intellia Therapeutics. Depending on the results, it could either boost investor confidence, leading to a potential increase in stock price, or it could have the opposite effect if the results are not favorable. However, without specific details about the data, it's difficult to predict the direction of the impact.